In 2014, a Phase 1 dose-escalation trial for OTX015 among individuals with advanced acute leukemia was the first to report the clinical activity of a BET inhibitor.162 In 46 individuals with CRPC, NMC, and NSCLC, birabresib (OTX015) was the subject of a Phase Ib research to assess its safety, effectiveness, and pharmacokinetics (NCT02259114).163 Birabresib 80 mg one day, administered continuously, is the recommended Phase II dosage for individuals with solid tumors. The gene discussed is DNER; the disease is nut midline carcinoma.